Justin Annes received his MD PHD degrees from New York University Medical School (2004) where he studied the regulation of Transforming Growth Factor-β (TGF-β) activity with Dr. Daniel Rifkin. He subsequently trained in Internal Medicine and Clinical Genetics at Brigham and Women’s Hospital (BWH) / Harvard Medical School (2004-2009). During this period, he worked with Dr. Douglas Melton at Harvard University on understanding the molecular pathways that govern islet β-cell growth. While a Harvard Medical School Instructor (2009-2012), his clinical and laboratory interests in Neuroendocrine Cell Biology led him to develop Hereditary Neuroendocrine Tumor (NET)-focused clinical programs at BWH and the Dana Farber Cancer Institute. In 2012, Dr. Annes moved to Stanford University, now Associate Professor, where his Laboratory explores the growth-control of islet β-cells and preclinical models SDHx mutation-dependent tumors. Among other impactful scientific accomplishments, Dr. Annes’ laboratory has developed the first mouse model of SDHB hereditary Pheochromocytoma and Paraganglioma (hPPGL) Syndrome. The goals of hPPGL research are to understand the molecular mechanisms that control SDHB-dependent tumor development, identify SDHB deficiency-related cellular weaknesses that may be therapeutically leveraged and advance SDHx-specific therapeutic leads through pre-clinical mouse models to human studies. Accordingly, Dr. Annes’ laboratory incorporates the power of medicinal chemistry to explore and develop novel therapeutic approaches to hPPGL-related tumors. Clinically, Dr. Annes directs a hereditary NET-focused Stanford Endocrine Oncology Clinic within the Endocrine Oncology Cancer Program (established in 2012), which cares for pre-symptomatic and symptomatic NET-affected patients and families.